{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Gyre Therapeutics, Inc.
Is Gyre Therapeutics, Inc. overvalued or undervalued?
As of May 9, 2025, Gyre Therapeutics, Inc. is considered overvalued with a P/E ratio of 105.51 and an EV to EBITDA ratio of 57.93, significantly higher than industry averages, and has underperformed the S&P 500 with a year-to-date return of -36.45%.
Is Gyre Therapeutics, Inc. technically bullish or bearish?
As of June 9, 2025, the technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and daily moving averages, despite some mildly bullish signals from the monthly MACD and Dow Theory.
What does Gyre Therapeutics, Inc. do?
Gyre Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently showing no dividend yield and negative financial metrics. No additional company details are available.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
